- AU$12.35m
- AU$15.41m
- AU$0.27m
Brief: Memphasys Says Potential Expedited FDA Pathway To US IVF Market
Brief: Memphasys Secures 3-Year Felix Agreement With Invido For A$674,000 Minimum Purchases
Australia's Memphasys soars on signing exclusive commercialisation agreement with NOVIVITAE
Brief: Memphasys Says Vietnamese Registration For Felix System Has Been Achieved In August 2026
Brief: Memphasys Secures UK Market Entry, Accelerates Commercial Expansion
Brief: Memphasys To Raise A$1.2 Million Via Share Placement At A$0.005 Per Share
Brief: Memphasys Executes Supply Agreement With Monash IVF Group
Brief: Memphasys Seeks Trading Halt
Australia's Memphasys surges on commercialisation deal in Vietnam
Brief: Memphasys Secures South-East Asian Commercialization Agreement
Australia's Memphasys advances on order wins in the Middle East
Brief: Memphasys Says ITL Orders 1000 Felix Cartridges Across Existing And New MENA Markets
Brief: Memphasys Appoints David Tasker As Non-Executive Chairman
Brief: Memphasys Ltd Says Middle East Commercial Operations Continue Uninterrupted
Brief: Memphasys Ltd Says Felix System Approved By TGA And Included On ARTG
Australia's Memphasys surges on regulatory nod for reproductive technology
Brief: Memphasys Seeks Trading Halt
Brief: Memphasys Ltd Says Hamad Medical Corp Commenced Commercial Ordering Of Felix Cartridges
Australia's Memphasys gains 40% on orders from Qatari customer